Stenting of native coronary arteries with a balloon-expandable stent was attempted in 226 patients after elective angioplasty. Delivery of the device was successful in 213 (94%) of the patients. Of these, 39 received aspirin and dipyridamole only (group 1) and 174 received aspirin, dipyridamole, and warfarin for 1-3 months (group 2). There was no abrupt closure (c1 day) or perioperative death in either group. In-hospital or perioperative complications in group 1 compared with group 2 were as follows: subacute closure (1-14 days), seven (18%) patients versus one (0.6%) patient, respectively, p<0.0001; myocardial infarction, five (13%) patients versus one (0.6%) patient, respectively; condition requiring urgent bypass surgery, one (2.5%) patient versus no patients, respectively. Thus, the incidence of major complications such as death, myocardial infarction, or a condition requiring urgent bypass surgery was 15% in group 1 and 0.6% in group 2. Clinical follow-up revealed that 92% of the patients were asymptomatic at 3 months after stenting compared with 6% before stenting (p<0.0001). Of the 13 patients who were symptomatic, nine underwent cardiac catheterization and, ultimately, successful elective coronary angioplasty or bypass surgery. We conclude that a high delivery success rate can be expected with this device and that clinical thrombosis is less frequent in anticoagulated patients than in nonanticoagulated patients. Furthermore, in this selected patient population, coronary stenting results in a low incidence of in-hospital and perioperative complications. Clinical success, defined by absence of symptoms, appears to be sustained at 3 months. (Circulation 1991;83:148- From the Cardiology Division of the Arizona Heart Institute Foundation (R.A.S, R.P., I.M.P., S
(c1 day) or perioperative death in either group. In-hospital or perioperative complications in group 1 compared with group 2 were as follows: subacute closure (1-14 days), seven (18%) patients versus one (0.6%) patient, respectively, p<0.0001; myocardial infarction, five (13%) patients versus one (0.6%) patient, respectively; condition requiring urgent bypass surgery, one (2.5%) patient versus no patients, respectively. Thus, the incidence of major complications such as death, myocardial infarction, or a condition requiring urgent bypass surgery was 15% in group 1 and 0.6% in group 2. Clinical follow-up revealed that 92% of the patients were asymptomatic at 3 months after stenting compared with 6% before stenting (p<0.0001). Of the 13 patients who were symptomatic, nine underwent cardiac catheterization and, ultimately, successful elective coronary angioplasty or bypass surgery. We conclude that a high delivery success rate can be expected with this device and that clinical thrombosis is less frequent in anticoagulated patients than in nonanticoagulated patients. Furthermore, in this selected patient population, coronary stenting results in a low incidence of in-hospital and perioperative complications. Clinical success, defined by absence of symptoms, appears to be sustained at 3 months. ( (occurring in 3-5% of patients4-6) and restenosis (occurring in 25-40% of patients7-8) remain as serious limitations to both the short-and long-term success of PTCA. Furthermore, perioperative occlusion after PTCA is an ominous predictor of both in-hospital and late ischemic complications,9-11 prompting investigators to explore permanent vascular implants as an alternative method to maintain vessel patency after angioplasty.12-29 One such device is a balloon-expandable intracoronary stent developed by Palmaz and colleagues. [18] [19] [20] [21] [22] [23] 25 The focus of this report is to describe the procedural results and short-term follow-up obtained during a multicenter investigation of this device.
Methods

Patient Selection
Patients were enrolled prospectively and consecutively into this multicenter study from December 1987 to September 1989. All United States centers participating in the stent (Johnson&Johnson, Warren (Figure la) . The stent measures 1.6 mm in diameter and 15 mm in length and is delivered percutaneously to the target site. The mechanical properties and biocompatibility profile of this stent have been previously described in multiple animal models. [18] [19] [20] 21, 29 The second stent used in this study was developed by Schatz et a125 as a modification of the Palmaz design to improve flexibility (Figure lb) . This stent is composed of two shorter (7 mm) segments of slotted tubes connected by a small (1 mm) bridging strut, a design that permits longitudinal flexibility while preserving the radial noncompliance of each component segment upon expansion. The favorable biocompatibility properties of this modified design have also been reported previously in animals. 25 Except for the first eight articulated stents, which had eight rows, all of the stents used in this study had 12 rows of slots.
Stent Implantation Procedure
After Institutional Review Board approval and informed consent, patients were brought to the catheterization laboratory in a fasting and sedated state, and catheterization was performed by either the brachial or femoral approach.
Rigid Stent
Balloon dilatation of the target lesion was performed in all patients by use of standard angioplasty techniques before stenting. Rigidity of the early prototype prevented antegrade passage of the stentloaded balloon through most guiding catheters. Therefore, the balloon catheter was first passed antegrade through a preselected guiding catheter (multipurpose or hockey-stick curves) so that the balloon extended well beyond the tip of the guiding catheter. A sterile balloon-expandable stent was then mounted on the balloon, mechanically crimped, and then withdrawn into the tip of the guiding catheter. The guiding catheter was then advanced to the aortic root and engaged in the appropriate coronary ostium. Next, the wire was passed antegrade across the freshly dilated target lesion, followed by the stentloaded balloon. Once centered, the stent was deployed by balloon inflation to 6-10 atm for 5-10 seconds. If the expanded stent diameter appeared too small, dilatation with a larger balloon was performed to further expand the stent to the appropriate diameter. Overdilatation by about 10% was considered optimal.22 Tandem placement with the rigid stent requires that the distal stent be placed first.
Articulated Stent
The technical advantage of this modified stent is that simple exchange techniques can be used for delivery. After routine dilatation, a stent-loaded balloon catheter was passed antegrade over a guidewire. Because the shorter segments "articulate" or flex around curves, the stent passes easily through most 8F or 9F guiding catheters. Once delivered to the target site, expansion was accomplished with a single balloon inflation of 6-10 atm for 5-10 seconds. If further expansion was required, the guidewire was left in place and the next larger-sized balloon was passed using standard exchange techniques. Tandem stents could be placed without removing the guidewire, offering an advantage over the rigid prototype.
Stent Retrieval
In the event of inability of the stent to pass the lesion, retrieval of the device was accomplished by withdrawal of the guiding catheter to the femoral sheath before attempting to pull the stent-loaded balloon into the guiding catheter.
Quantitative Coronary Analysis
Quantitative coronary analysis was performed with the use of a computer-based coronary angiography analysis system with automatic edge detection (ADAC, Milpitas, Calif.). Paired cine frames, in orthogonal views wherever possible, were selected from the preangioplasty and post-stent cineangiograms (n-138; the remainder of the films was unavailable) and then reviewed by three observers. The day-to-day observer variability was 0.16 mm for absolute diameter and less than 5% for percent steno-sis. Quantitative measurements of stenosis diameter (in millimeters) were determined by using the guiding catheter as a scaling device. Minimal lumen diameter was reported and typically occurred at the central gap within the stent. Proximal and distal segments, considered to be without coronary disease and outside the stented segment, were selected and averaged; this average value was considered to be the diameter of the normal reference vessel and was used to determine the percentage diameter stenosis.
Drug Regimen
The following drug regimen was based on thrombogenicity testing in animals21: Aspirin (325 mg p.o. daily) and dipyridamole (75 mg p.o. three times a day) were begun at least 24-48 hours before stenting, with a calcium channel blocker beginning at least 1 day before the procedure. All patients were treated with low molecular weight dextran 40 (100 ml/hr i.v.) 2 hours before stent deployment and continued for a total dose of 1 1. Heparin (10,000 units) was given as an initial intravenous dose in the catheterization laboratory followed by approximately 2,500 units/hr thereafter during the procedure. Activated clotting times were measured when available and maintained at 2 to 2.5 times baseline. Intracoronary urokinase (up to 500,000 units) was administered only if thrombus was visible before or after stent placement.
Intracoronary nitroglycerin (200 gg) was given once before and once after stent deployment. After the procedure, a heparin infusion was begun to maintain a partial thromboplastin time at approximately 1.5-2.5 times control and continued for at least 24 hours.
Aspirin, dipyridamole, and calcium channel blockers were continued for 3 months, after which the dipyridamole and calcium channel blockers were discontinued. Warfarin was not administered routinely to the first 39 patients, but due to subacute thrombosis, all patients were treated thereafter with warfarin (prothrombin time between 16 and 18 seconds) in addition to aspirin and dipyridamole. Warfarin or subcutaneous heparin was continued for 1-3 months unless intercurrent bleeding complications required therapy adjustment. Poststent Course and Evaluation Sheaths were removed between 2-24 hours after stenting, depending on operator preference, and after heparin had been discontinued for 2-4 hours. Heparin was restarted 2-4 hours after sheath removal. Broad spectrum antibiotics were given for 24 hours intravenously if sheaths were left in place for more than 2 hours after the procedure. Repeat angiography of the treatment vessel was performed at 24 hours in the initial 66 patients of the study. In the absence of complications, or oral anticoagulation therapy, patients were discharged approximately 48 hours after stent placement. If oral anticoagulants were used, discharge was delayed until the prothrombin time reached approximately 16-18 seconds and the heparin could be safely discontinued (usually 2 or 4 days after stent placement).
Posthospitalization Course and Evaluation
Patients were seen at 2 weeks, and 1, 2, and 3 months. Clinical status up to 3 months only is the subject of this paper. Diagnostic angiography was performed at operator discretion at any time. Treatment with antibiotics similar to infective endocarditis prophylaxis was recommended for 3 months after stenting.
Definition of End Points
The following end points were examined: 1) successful delivery: complete passage of the stent across the target lesion with full expansion of the stent to the desired diameter, 2) failed delivery: failure to pass the stent through the guiding catheter into the coronary artery, failure to pass it completely across the target lesion, or failure to expand the stent to its desired diameter, 3) proximal deployment: those instances of failed delivery when the stent could be advanced only partially across the target lesion but was deployed nonetheless by full expansion, 4) acute closure: total thrombosis of the stent within 24 hours of delivery, and 5) subacute closure: total stent thrombosis between 24 hours and 2 weeks after delivery.
Statistical Analysis
Interactions between categorical variables such as the involved vessel and delivery success were analyzed by Fisher's exact test or the x2 test. Treatment effects on continuous variables such as percent stenosis of object vessel were examined by the twotailed t test. Distributions of continuous data are described as mean±SD. Effects were interpreted as significant-when the null hypothesis could be rejected at the 95% confidence level.
Results
Patient Population
After informed consent was obtained, 226 patients were enrolled prospectively into this FDA-approved protocol. Table 1 Of the 213 patients who had successful delivery of either the rigid or the articulated stent, 39 were discharged without anticoagulation (group 1), two were treated with subcutaneous home heparin (operator preference), and the remainder (172 patients) were treated with warfarin (group 2). Percent stenosis decreased from 73+15% before angioplasty to 16+12 after stenting (p<0.0001). Follow-up angiography 1 day after stenting in the first 66 patients revealed no change in the vessel diameter at the stented site or migration of the device (Figure 3) . The mean final stent diameter was 2.7+0.5 mm. The target artery diameter ranged from 2.0 to 4.0 mm.
Three patients who received the rigid stent required intracoronary urokinase ranging in dosage from 70,000 to 500,000 units for asymptomatic nonocclusive thrombus seen within the lesion before placing the stent. None of these patients received anticoagulation therapy on discharge. Two patients who received the articulated stent required intracoronary urokinase ranging in dosage from 75,000 to 250,000 units for luminal thrombus after stent delivery. Figures 4-6 illustrate angiographic examples of successful stent delivery.
Complications Table 4 reveals the complications of those patients who did not receive anticoagulation after successful stent delivery (group 1) versus those who did (group 2) and in the total population in whom stent delivery was attempted.
Group 1: Nonanticoagulated. Of the 39 patients in this group, 17 received the rigid stent and 22 received the articulated stent. No patients suffered acute closure, but seven (18%) patients (all of whom received articulated stents) developed subacute thrombotic closure within 2-11 days after stenting, five of whom sustained myocardial infarction. One remains asymptomatic with excellent collaterals, one underwent elective bypass surgery, one underwent urgent bypass surgery after successful recanalization, three remained patent angiographically after successful recanalization (although each suffered non-Q wave myocardial infarction), and one patient suffered a 0 wave infarction (creatine phosphokinase 2,800) and remained occluded after failed attempts at re- Group 2: Anticoagulated. The 174 patients in this group each received the articulated stent. There was no case of abrupt closure in this group and only one (0.6%) case of subacute closure after stenting (day 10) despite adequate anticoagulation. This patient had received two stents with 75% overlap and then developed thrombotic occlusion with acute myocardial infarction (creatine phosphokinase 3,000) at 10 days that was resistant to recanalization. The patient ultimately underwent successful elective bypass surgery.
Nonocclusive thrombotic events occurred in two patients. One developed a brief episode of chest pain at 28 hours after stenting and angiographically demonstrated a small thrombus within the stent, which was treated successfully with intracoronary urokinase (50,000 units). Although there was no further angina, this patient went on to elective bypass surgery for associated left main coronary disease. Another patient who inadvertently had not received dextran before the operation developed a brief episode of angina 1-2 hours after stenting, which resolved after a heparin bolus and nitrates. Immediate angiography revealed minimal nonocclusive thrombus within the stent, which resolved with intracoronary urokinase, intravenous dextran, and repeat dilatation. The patient recovered uneventfully and remains asymptomatic at 3 months of clinical follow-up.
There was one death from an intracranial hemorrhage 8 weeks after successful stenting of a totally occluded circumflex artery (Figures 6a and 6b ). Autopsy revealed a patent artery with a thin layer of endothelialized neointimal growth (300-600 gm) overlying the area of stent overlap, which was highly cellular compared with the relatively acellular and thin neointimal layer (<50 ,um) at either end of the nonoverlapped stents (Figures 6e and 6f ).
There were two cases of tamponade. One occurred 1 month after stenting in a patient in group 2 with uremic pericarditis. Thoracotomy revealed blood in the pericardium, which was treated successfully with pericardiectomy. Angiographic follow-up revealed that the stented arterial segment remained widely patent. A second patient developed tamponade acutely as a result of right ventricular perforation with a pacing wire, which was treated successfully with surgery.
Four patients in group 2 developed gastrointestinal bleeding requiring transfusion, eight developed hematoma requiring surgery or transfusion, and two developed pseudoaneurysms for a vascular complication rate of 10 of 174 (5.7%). There were no deaths related to stent thrombosis.
Overall complications. Of the 213 patients in whom stent delivery was successful, seven (3.3%; six in group 1 and one in group 2, p<0.0006) suffered a major complication defined as death, myocardial infarction, or a condition requiring urgent bypass surgery. Other complications such as bleeding and tamponade occurred in 8.9% of these patients (Table  4) . Stent embolization occurred in eight (2.5%) of 321 stent delivery attempts and in seven (3%) of 226 patients. One additional patient in whom stent delivery failed experienced successful urgent bypass, and another died after conventional PTCA, yielding an overall major complication rate among patients in whom stent delivery was attempted of 4% (9/226). The obvious cosmetic improvement in vessel appearance seen in this study after stenting (especially in dissected arteries, Figure 2) (Figures 6a-6f) .
In this study, the lower incidence of thrombosis after anticoagulation suggests that this particular stent design may be relatively nonthrombogenic in the immediate postoperative period compared with other stent designs as described in published reports. 30 anticoagulation and raises the question of incomplete endothelialization with the spring design. Coronary spasm has also been reported with spring devices, the incidence of which appears to diminish with intracoronary nifedipine. 38 Patient selection may explain these different clinical outcomes to some degree; only elective PTCA patients with collaterals were stented in this study, whereas 26% of patients in the study of Sigwart et a137 were stented after abrupt closure, in which enhanced thrombogenicity and vasoactivity is common.
Analysis of clinical status up to 3 months after stenting reveals a relatively stable postoperative course: 92% of the patients remained asymptomatic (compared with 6.5% before the operation; p <0.0001), and only 4.3% required elective revascularization with either PTCA or coronary artery bypass graft after hospital discharge. Interpretation of the postoperative status, however, is complicated by the presence of collaterals in the study population, so that completed angiographic follow-up will be required to assess long-term patency.
Limitations
A technical limitation of this and other stents is relative radiolucency resulting from small mass. Poor stent visualization may contribute to imprecise placement, unnecessary overlapping, or excessive gaps between stents when placed in tandem or failure to recognize dislodgement of the stent from the delivery system, resulting in incomplete expansion or embolization of the stent. A second limitation is that without a protective sheath to separate the stent from the vessel wall during delivery, there is a potential risk of intimal damage or snagging of the stent on mural plaques, preventing optimal placement or reliable retrieval. The possibility of passive deformity of the leading edge of the stent during passage and potential snagging has encouraged development of a protective sheath for complex lesions.
Patient entry into the study was also highly selective for relatively proximal lesions in large vessels without tortuosity and, as such, may have introduced bias toward a more favorable outcome. This was offset somewhat by the high incidence of patients in the study with unstable angina (37%) and multiple prior PTCA procedure (69%).
Conclusion
We conclude from this initial study that in a carefully selected group of patients who undergo elective coronary stenting 1) the rigid prototype has limited clinical use due to its inflexibility and propensity for delivery complications, 2) the articulated design is easier to deliver than the prototype, but despite improved operator experience the stent still fails to pass the target lesion in a small number of cases, 3) the risk of acute closure due to thrombosis appears to be very low with this stent, but 4) subacute thrombotic closure of the stent occurs frequently without anticoagulation and may be, in part, related to omission of antiplatelet agents or imprecise place-ment of multiple stents with a high degree of overlap. The risk period of thrombosis appears to be in the first 2 weeks after placement; thus, we recommend a short course of anticoagulation in addition to antiplatelet agents in all patients.
We are encouraged by these early clinical results and find the procedure to be safe and effective in this carefully selected patient population. Whether this particular stent will solve the greater problem of restenosis can only be answered by analysis of longterm angiographic follow-up, which is forthcoming. We are optimistic that a role may exist for the elective use of coronary stents after angioplasty; however, further studies will be required to better define this role.
